Pharma-Bio Serv, Inc. (PBSV) Financial Statements (2023 and Earlier)

Company Profile

Business Address INDUSTRIAL ZONE STREET 1
DORADO, 00646
State of Incorp.
Fiscal Year End October 31
Industry (SIC) 8742 - Management Consulting Services (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

1/31/2022
TTM
10/31/2021
10/31/2020
10/31/2019
10/31/2018
10/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments15,352 17,13815,49016,07411,778
Cash and cash equivalents15,352 17,13815,49016,03011,752
Short-term investments    4427
Receivables5,046 10,97810,0316,9437,208
Other current assets  469454394550
Other undisclosed current assets624     
Total current assets:21,022 28,58425,97523,41219,537
Noncurrent Assets
Operating lease, right-of-use asset606 847 
Property, plant and equipment93 2182912982,391
Long-term investments and receivables    1,250 
Accounts and financing receivable, after allowance for credit loss    1,250 
Other noncurrent assets353 270367418423
Total noncurrent assets:1,053 1,3356581,9672,813
TOTAL ASSETS:22,074 29,91926,63325,37822,350
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,690 1,9381,5902,1401,527
Taxes payable1,851 3923444122
Interest and dividends payable   1,725  
Other undisclosed accounts payable and accrued liabilities(161) 1,546(479)1,7281,525
Debt  1,299111414
Other undisclosed current liabilities632 5552,0694122
Total current liabilities:2,322 3,7933,6712,5661,543
Noncurrent Liabilities
Long-term debt and lease obligation453 685674660
Finance lease, liability  55 
Capital lease obligations674660
Operating lease, liability453 630 
Liabilities, other than long-term debt  2,0622,2882,503 
Accounts payable and accrued liabilities  2,0622,2702,485 
Other liabilities   1818 
Other undisclosed noncurrent liabilities1,415 662   
Total noncurrent liabilities:2,322 3,4092,3552,54960
Total liabilities:4,644 7,2026,0265,1151,603
Stockholders' equity
Stockholders' equity attributable to parent17,431 22,71720,60820,26420,747
Common stock2 2222
Treasury stock, value(475) (394)(393)(305)(248)
Additional paid in capital1,495 1,4241,3811,3471,295
Accumulated other comprehensive income119 161144108138
Retained earnings16,290 21,52419,47319,11119,560
Total stockholders' equity:17,431 22,71720,60820,26420,747
TOTAL LIABILITIES AND EQUITY:22,074 29,91926,63325,37822,350

Income Statement (P&L) ($ in thousands)

1/31/2022
TTM
10/31/2021
10/31/2020
10/31/2019
10/31/2018
10/31/2017
Revenues15,604 21,56419,50717,79715,579
Revenue, net15,579
Cost of revenue(11,606) (14,898)(13,330)(12,111)(11,968)
Cost of goods and services sold     (11,968)
Gross profit:3,999 6,6676,1775,6873,611
Operating expenses(8,080) (4,441)(4,433)(4,593)(5,036)
Other undisclosed operating income (loss)   343(2,356) 
Operating income (loss):(4,082) 2,2262,087(1,262)(1,425)
Nonoperating income1,955 6452743614
Other nonoperating income1,955     
Income (loss) from continuing operations before equity method investments, income taxes:(2,127) 2,2902,614(826)(1,411)
Other undisclosed income (loss) from continuing operations before income taxes   (391)2,350 
Income (loss) from continuing operations before income taxes:(2,127) 2,2902,2231,524(1,411)
Income tax expense(165) (239)(136)(2,786)(4)
Income (loss) from continuing operations:(2,292) 2,0512,087(1,262)(1,415)
Income from discontinued operations    2,541 
Net income (loss) available to common stockholders, diluted:(2,292) 2,0512,0871,280(1,415)

Comprehensive Income ($ in thousands)

1/31/2022
TTM
10/31/2021
10/31/2020
10/31/2019
10/31/2018
10/31/2017
Net income (loss):(2,292) 2,0512,0871,280(1,415)
Comprehensive income (loss):(2,292) 2,0512,0871,280(1,415)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(70) 1736(30)304
Comprehensive income (loss), net of tax, attributable to parent:(2,362) 2,0682,1231,250(1,111)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: